Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
October 16, 2023
NodThera Announces First Patients Dosed in a Phase Ib/IIa Cardiovascular Risk Trial of NLRP3 Inflammasome Inhibitor NT-0796
October 10, 2023
Precede Biosciences Emerges From Stealth to Dramatically Impact Precision Medicine with a First-In-Class Liquid Biopsy Platform
September 27, 2023
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
September 26, 2023
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations
September 25, 2023
Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
September 21, 2023
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 20, 2023
scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives
September 13, 2023
TMRW Life Sciences Receives CE Mark for the CryoRobot Select, its Next-Generation Automated Platform to Safely Manage and Store Frozen Eggs and Embryos
September 12, 2023
IDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
September 12, 2023
Dianthus Therapeutics Announces Positive Top-Line Phase 1 Data and Debuts Trading on NASDAQ as DNTH
« Previous Page
1
…
4
5
6
7
8
…
118
Next Page »